black box warning for semaglutide Popular weight-loss drugs shouldn't carry suicide warnings, FDA says Semaglutide & weight loss –

Wegovy HD is a higher-dose semaglutide (7.2 mg once weekly) that the US FDA approved in 2025 for adults with obesity who have already tolerated the 2.4 mg dose for at least four weeks and still need further weight reduction

Employment screening programs were created to identify impairment from recreational drugs

The most common side effects are gastrointestinal (think: constipation, diarrhea, or an upset stomach)

It must be adapted based on medical history, response to treatment, and overall health

Archived from the original on February 15, 2017

All cases were classified as mild with no necrotising pancreatitis observed and approximately 80% had confounding risk factors including gallstones or alcohol use